IN2014MN02101A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN02101A IN2014MN02101A IN2101MUN2014A IN2014MN02101A IN 2014MN02101 A IN2014MN02101 A IN 2014MN02101A IN 2101MUN2014 A IN2101MUN2014 A IN 2101MUN2014A IN 2014MN02101 A IN2014MN02101 A IN 2014MN02101A
- Authority
- IN
- India
- Prior art keywords
- heart failure
- present
- chronic heart
- stable chronic
- procalcitonin
- Prior art date
Links
- 206010007558 Cardiac failure chronic Diseases 0.000 abstract 2
- 108010048233 Procalcitonin Proteins 0.000 abstract 2
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 abstract 2
- 230000002411 adverse Effects 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/585—Calcitonins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/54—Determining the risk of relapse
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12163921 | 2012-04-12 | ||
| PCT/EP2013/057626 WO2013153177A1 (en) | 2012-04-12 | 2013-04-11 | Prognosis of adverse events in patients with suspected chronic heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02101A true IN2014MN02101A (OSRAM) | 2015-08-28 |
Family
ID=48050768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2101MUN2014 IN2014MN02101A (OSRAM) | 2012-04-12 | 2013-04-11 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9488659B2 (OSRAM) |
| EP (1) | EP2836841B1 (OSRAM) |
| JP (1) | JP5945063B2 (OSRAM) |
| CN (1) | CN104303061B (OSRAM) |
| BR (1) | BR112014025189B1 (OSRAM) |
| IN (1) | IN2014MN02101A (OSRAM) |
| RU (1) | RU2672561C2 (OSRAM) |
| WO (1) | WO2013153177A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5945063B2 (ja) * | 2012-04-12 | 2016-07-05 | ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 慢性心不全が疑われる患者における有害事象の予後 |
| EP2990800A1 (en) * | 2014-08-29 | 2016-03-02 | Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol | Neprilysin as heartfailure (HF) prognostic marker |
| WO2016123163A2 (en) | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
| US10368774B2 (en) | 2015-07-30 | 2019-08-06 | Medtronic, Inc. | Absolute intrathoracic impedance based scheme to stratify patients for risk of a heart failure event |
| CN105929152B (zh) * | 2016-07-15 | 2018-06-26 | 安徽国科生物科技有限公司 | 一种用于降钙素原检测的智能检测仪 |
| EP4421088A3 (en) * | 2017-02-06 | 2024-12-04 | Uit de Krempe IP B.V. | C-peptide's interaction with elastin receptor, a blueprint for understanding vascular disease |
| CN108931658A (zh) * | 2018-04-16 | 2018-12-04 | 上海交通大学医学院附属瑞金医院 | 用于诊断心力衰竭合并症及预后评估的血清标记物 |
| US12400762B2 (en) | 2018-12-11 | 2025-08-26 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy |
| US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
| US12001939B2 (en) | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
| US12322100B2 (en) | 2018-12-11 | 2025-06-03 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity |
| US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
| RU2766252C1 (ru) * | 2021-04-13 | 2022-02-10 | федеральное государственное бюджетное образовательное учреждение высшего образования "Ульяновский государственный университет" | Способ прогнозирования риска смерти у больных с хронической сердечной недостаточностью с использованием эндогенного эритропоэтина сыворотки крови |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4281061A (en) * | 1979-07-27 | 1981-07-28 | Syva Company | Double antibody for enhanced sensitivity in immunoassay |
| DE19847690A1 (de) * | 1998-10-15 | 2000-04-20 | Brahms Diagnostica Gmbh | Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen |
| DE102006046996A1 (de) * | 2006-10-01 | 2008-04-03 | Brahms Aktiengesellschaft | Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz |
| CN101029897A (zh) * | 2007-02-09 | 2007-09-05 | 深圳市新产业生物医学工程有限公司 | 一种降钙素原测试试剂盒及其测试方法 |
| DE102007009751A1 (de) * | 2007-02-28 | 2008-09-04 | B.R.A.H.M.S Aktiengesellschaft | Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens |
| DE602008021800C5 (de) * | 2007-08-03 | 2022-05-05 | B.R.A.H.M.S Gmbh | Antibiotikum zur Behandlung von lokaler Infektion |
| EP2101178A1 (en) | 2008-03-12 | 2009-09-16 | BRAHMS Aktiengesellschaft | Use of Procalcitonin (PCT) in prognosis following acute coronary syndromes |
| RU2357250C1 (ru) * | 2007-12-10 | 2009-05-27 | Федеральное государственное учреждение "Федеральный центр сердца, крови и эндокринологии имени В.А. Алмазова Федерального агентства по высокотехнологичной медицинской помощи" | Способ прогнозирования течения хронической сердечной недостаточности |
| PL2419741T3 (pl) | 2009-04-14 | 2020-01-31 | B.R.A.H.M.S Gmbh | Ocena ryzyka antybiotykoterapii u pacjentów z niezakaźną chorobą podstawową przez oznaczanie stężenia prokalcytoniny |
| EP2284540A1 (en) * | 2009-07-31 | 2011-02-16 | BIOCRATES Life Sciences AG | Method of diagnosing organ failure |
| CN201886025U (zh) * | 2010-12-10 | 2011-06-29 | 四川迈克生物科技股份有限公司 | 一种快速定量检测降钙素原免疫层析试纸条 |
| JP5945063B2 (ja) * | 2012-04-12 | 2016-07-05 | ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 慢性心不全が疑われる患者における有害事象の予後 |
-
2013
- 2013-04-11 JP JP2015504958A patent/JP5945063B2/ja active Active
- 2013-04-11 US US14/391,953 patent/US9488659B2/en active Active
- 2013-04-11 EP EP13714980.3A patent/EP2836841B1/en active Active
- 2013-04-11 CN CN201380019816.2A patent/CN104303061B/zh active Active
- 2013-04-11 WO PCT/EP2013/057626 patent/WO2013153177A1/en not_active Ceased
- 2013-04-11 RU RU2014145259A patent/RU2672561C2/ru active
- 2013-04-11 IN IN2101MUN2014 patent/IN2014MN02101A/en unknown
- 2013-04-11 BR BR112014025189A patent/BR112014025189B1/pt active IP Right Grant
-
2016
- 2016-07-15 US US15/211,802 patent/US9753039B2/en active Active
-
2017
- 2017-09-01 US US15/693,880 patent/US20170370940A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013153177A1 (en) | 2013-10-17 |
| BR112014025189B1 (pt) | 2020-04-07 |
| US20150079696A1 (en) | 2015-03-19 |
| RU2014145259A (ru) | 2016-06-10 |
| JP5945063B2 (ja) | 2016-07-05 |
| RU2672561C2 (ru) | 2018-11-16 |
| EP2836841B1 (en) | 2022-01-05 |
| EP2836841A1 (en) | 2015-02-18 |
| CN104303061B (zh) | 2017-05-31 |
| JP2015515630A (ja) | 2015-05-28 |
| CN104303061A (zh) | 2015-01-21 |
| US9488659B2 (en) | 2016-11-08 |
| US9753039B2 (en) | 2017-09-05 |
| HK1203611A1 (en) | 2015-10-30 |
| US20170370940A1 (en) | 2017-12-28 |
| BR112014025189A2 (pt) | 2017-07-11 |
| US20160320411A1 (en) | 2016-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN02101A (OSRAM) | ||
| MY174894A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation | |
| JO3131B1 (ar) | مركبات كيميائية | |
| EA201400119A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
| MX367046B (es) | Marcadores especificos de via para diagnosticar sindrome del intestino irritable. | |
| EA201391187A1 (ru) | Способ диагностики злокачественной опухоли и набор для диагностики путем измерения активности nk-клеток | |
| UA109271C2 (uk) | Комбінація фітоканабіноїдів та темозоламіду для лікування гліоми | |
| UA116196C2 (uk) | Синтетичний міметик апеліну для лікування серцевої недостатності | |
| MX2014000363A (es) | Anticuerpos monoclonales inhibidores anti-factor xii-xiia. | |
| HK1199290A1 (en) | Methods and compositions for the treatment and diagnosis of breast cancer | |
| MX349514B (es) | Agentes de reversion anticoagulante. | |
| EA201500997A1 (ru) | Терапевтические применения эмпаглифлозина | |
| EA201490883A1 (ru) | ПРИМЕНЕНИЕ АНТИТЕЛА К α-СИНУКЛЕИНУ ДЛЯ ДИАГНОСТИКИ ПОВЫШЕННОГО УРОВНЯ α-СИНУКЛЕИНА В МОЗГЕ | |
| BR112012016894A2 (pt) | lactobacilos com ação antioxidante. | |
| NZ716643A (en) | Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event | |
| WO2015013508A3 (en) | Methods for diagnosing and treating immune disease | |
| EA201591773A1 (ru) | Макроциклические ингибиторы rip2-киназы | |
| MX2016001195A (es) | Metodos para mejorar sintomas de asma mediante el uso de benralizumab. | |
| EA201270315A1 (ru) | Новые формы полициклического соединения | |
| HK1215069A1 (zh) | 肺中的細菌負荷位置的確定 | |
| IN2014DN08312A (OSRAM) | ||
| HUE042708T2 (hu) | Szívelégtelenség diagnosztika | |
| MY170453A (en) | Etching material | |
| EA201391772A1 (ru) | Способ диагностики ревматоидного артрита | |
| MX364003B (es) | Tratamiento de resistencia a la insulina a traves de inhibidores del factor de transcripcion tsc22d4. |